Responses
Regular and young investigator award abstracts
Clinical trials completed
258 Scientific correlatives from LCCC 1525: a phase II study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.
